title: Retinal guanylyl cyclase isozyme 1 is the preferential in vivo target for constitutively active GCAP1 mutants causing congenital degeneration of photoreceptors.
abstract: Two calcium-sensitive guanylyl cyclase activating proteins (GCAP1 and GCAP2) activate cGMP synthesis in photoreceptor by retinal membrane guanylyl cyclase isozymes (RetGC1 and RetGC2) to expedite recovery, but calcium-insensitive constitutively active GCAP1 mutants cause photoreceptor degeneration in human patients and transgenic mice. Although GCAP1 and GCAP2 can both activate RetGC1 and RetGC2 in vitro, we find that GCAP1 selectively regulates RetGC1 in vivo. Furthermore, elimination of RetGC1 but not RetGC2 isozyme reverses abnormal calcium sensitivity of cGMP synthesis and rescues mouse rods in transgenic mice expressing GCAP1 mutants causing photoreceptor disease. Rods expressing mutant GCAP1 not only survive in the absence of RetGC1 but also remain functional, albeit with reduced electroretinography (ERG) amplitudes typical of RetGC1-/- genotype. The rod ERG recovery from a strong flash, only slightly affected in both RetGC1-/- and RetGC2-/- mice, becomes very slow in RetGC1-/- but not RetGC2-/- mice when GCAP2 is not available to provide Ca²⁺ feedback to the remaining RetGC isozyme. The intrinsic biochemical properties of RetGC and GCAP determined in vitro do not explain the observed phenomena. Instead, our results argue that there must be a cellular mechanism that limits GCAP1 access to RetGC2 and makes RetGC1 isozyme a preferential target for the disease-causing GCAP1 mutants. A more general conclusion from our findings is that nondiscriminatory interactions between homologous effector enzymes and their regulatory proteins permitted by their intrinsic biochemical properties can be effectively restricted in a living photoreceptor.
authors.affiliation: Department of Basic Sciences and Pennsylvania College of Optometry, Salus University, Elkins Park, Pennsylvania 19027, USA.
authors.forename: Elena V
authors.initials: EV
authors.lastname: Olshevskaya
authors.forename: Igor V
authors.initials: IV
authors.lastname: Peshenko
authors.forename: Andrey B
authors.initials: AB
authors.lastname: Savchenko
authors.forename: Alexander M
authors.initials: AM
authors.lastname: Dizhoor
mesh_terms: D000818:Animals; D002118:Calcium / Q000494:pharmacology; D006152:Cyclic GMP / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004596:Electroretinography / Q000379:methods; D005260:Female; D006162:Guanylate Cyclase / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D051604:Guanylate Cyclase-Activating Proteins / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D007527:Isoenzymes / Q000235:genetics / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008822:Mice, Transgenic; D012160:Retina / Q000187:drug effects / Q000201:enzymology / Q000502:physiology*; D012162:Retinal Degeneration / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D017948:Retinal Rod Photoreceptor Cells / Q000201:enzymology / Q000473:pathology / Q000502:physiology
chemical_list: D051604:Guanylate Cyclase-Activating Proteins; D007527:Isoenzymes; D006162:Guanylate Cyclase; D006152:Cyclic GMP; D002118:Calcium